- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04968366
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
February 7, 2024 updated by: Yang Zhang, Beijing Tiantan Hospital
Phase I Clinical Study of Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
This is a single-center, single-arm phase I study to determine the safety and preliminary efficacy of autologous dendritic cells (DCs) loaded with multiple tumor neoantigen peptides administered as a cancer-treatment vaccine to treat adult postoperative patients with newly-diagnosed glioblastoma, in combination with the standard-of-care Temozolomide (TMZ) chemotherapy.
Study Overview
Status
Active, not recruiting
Conditions
Detailed Description
This is a single-center, single-arm phase I study to determine the safety and preliminary efficacy of autologous dendritic cells (DCs) loaded with multiple tumor neoantigen peptides administered as a cancer-treatment vaccination for the treatment of newly-diagnosed glioblastoma (GBM).
The subjects are adult GBM patients who have undergone surgical resection.
After the completion of TMZ concurrent chemoradiation, and, during conventional adjuvant TMZ chemotherapy, subjects will receive autologous DC vaccine treatments as scheduled.
Ten subjects will be enrolled.
The autologous genetic-modification-free DC cells will be loaded with multiple tumor neoantigen peptides and administered (i.d) to subjects.
After 5 injections, the investigator will review subject's tolerance and compliance, and decide whether or not to administer more DC vaccines up to 8 injections.
For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of TMZ adjuvant chemotherapy to assess patient's immune response.
According to the result, investigators will be decided whether to perform more 1-2 treatment cycles (5-8 infections/cycle) to strengthen the effectiveness.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yang Zhang, Dr.
- Phone Number: 01059976516
- Email: zhangyang8025@yeah.net
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Beijing Tiantan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age from 18 to 75 years (including 18 and 75 years old);
- Newly-diagnosed glioblastoma confirmed by histopathological exams;
- IDH1- and IDH2-wild-type gliomas;
- Extent of resection of enhancing lesions > 90%;
- Karnofsky Performance Score(KPS) ≥ 60%;
- Adequate organ functions:
The absolute value of white blood cells ≥ 2.5×10 9/L; Hemoglobin levels> 100 g/L; Platelet counts > 100×109/L; Levels of Alanine aminotransferase, aspartate aminotransferase <2.5 x ULN; Serum creatinine levels <1.5 x ULN.
Exclusion Criteria:
- Subjects with any other active malignancy;
- Subjects received the placement of Carmustine implants within 6 months before the inclusion;
- Subjects with active HBC, HCV or HIV infection;
- Subjects with grade 2 -3 hypertension or uncontrolled hypertension;
- Subjects with severe cardio- or cerebro- vascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, etc.;
- Subjects with uncontrolled autoimmune diseases such as hemolytic anemia, psoriasis and rheumatoid arthritis, etc.;
- Subjects with severe or uncontrolled psychiatric diseases or condition that could increase adverse events or interfere the evaluation of outcomes;
- Subjects receiving immunosuppressants after organ transplantation;
- Within four weeks before the DC vaccinations, subjects receiving systemic administration of steroids with dosage more than 10mg/d prednisone or the equivalent doses of other steroids ( not including inhaled corticosteroid);
- Subjects with unstable pulmonary embolism, deep venous embolism, or other major arterial and venous thromboembolic events that occur within 30 days before the enrollment; receiving ongoing anticoagulant therapy;
- Subjects in pregnancy or breastfeeding, or those who plan to become pregnant during treatment or within 2 months after the end of treatment;
- Within the 14 days before enrollment, subjects with active infections or uncontrolled infections that require systemic antibiotic treatment (except for simple urinary tract infections or upper respiratory tract infections);
- Subjects who have received other vaccine therapies or gene-modified cell therapy before enrollment;
- Subjects with number of the predicted neoantigen peptides less than 5;
- Subjects with other conditions that would interfere trial participation at the investigator's discretion;
- Subjects with medical conditions that affect signing the written informed consent or complying with the research procedures; or patients who are unwilling or unable to comply with the research procedures;
- Subjects who participated or are participating in other clinical trials within 4 weeks before enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DC vaccine group
Subjects will receive five to eight doses of the DC vaccine through i.d.
injection into regions near to the groin and axillary during they receive TMZ adjuvant chemotherapy
|
Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides.
DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation.
After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections.
For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response.
According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness
Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events (AEs)
Time Frame: All the AEs were recorded from the first shot to 8 weeks after the last shot.
|
AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
|
All the AEs were recorded from the first shot to 8 weeks after the last shot.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportions of patients with positive peripheral tumor specific immune response after the DC vaccinations
Time Frame: start from the inclusion timepoint to one week after the last injection.
|
The peripheral tumor specific immune response is measured by the IFN-γ release ELISPOT assay, using the peripheral blood mononuclear cells (PBMCs) that are collected before the vaccine injection (baseline), one week after the 3r, 5th and the last injection, respectively.
The positive response is defined as "≥ 55 spot-forming cells in each million PBMCs" or "number of spot-forming cells increase by 3-fold after the DC vaccination compared with the baseline".
|
start from the inclusion timepoint to one week after the last injection.
|
Progression-free survival
Time Frame: From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
months from the date of surgery to tumor recurrence or progression
|
From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Overall survival
Time Frame: From date of surgery until the date of death from any cause, assessed up to 60 months
|
months from the date of surgery to death
|
From date of surgery until the date of death from any cause, assessed up to 60 months
|
Rate of the patients who survive for more than one year after surgery in all the included patients who receive the DC vaccine
Time Frame: From date of surgery until one year after surgery
|
One-year survival rate
|
From date of surgery until one year after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Nan Ji, Dr., Beijing Tiantan Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 30, 2021
Primary Completion (Estimated)
March 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
July 6, 2021
First Submitted That Met QC Criteria
July 16, 2021
First Posted (Actual)
July 20, 2021
Study Record Updates
Last Update Posted (Estimated)
February 9, 2024
Last Update Submitted That Met QC Criteria
February 7, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
Other Study ID Numbers
- KY 2021-021-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme of Brain
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Mashhad University of Medical SciencesUnknownEfficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade GliomaGlioblastoma Multiforme of Brain | Anaplastic Astrocytoma of BrainIran, Islamic Republic of
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
TVAX BiomedicalFDA Office of Orphan Products DevelopmentRecruitingGlioblastoma Multiforme of BrainUnited States
-
Shenzhen Geno-Immune Medical InstituteEnrolling by invitationGlioblastoma Multiforme | Glioblastoma Multiforme of BrainChina
-
University of Roma La SapienzaCompletedGlioblastoma Multiforme of Brain
-
Imperial College LondonRecruitingGlioblastoma Multiforme of BrainUnited Kingdom
Clinical Trials on Autologous dendritic cells pulsed with multiple neoantigen peptides.
-
The Republican Research and Practical Center for...Belarusian State Medical UniversityCompletedPancreatic Neoplasms | Dendritic CellsBelarus
-
Statens Serum InstitutRigshospitalet, Denmark; Hvidovre University HospitalCompleted
-
Henan Cancer HospitalCttqUnknown
-
Sara VareaCompletedMultiple Sclerosis | Neuromyelitis OpticaSpain
-
University of Sao Paulo General HospitalNot yet recruiting
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV Infections | HIV-1 InfectionUnited States
-
Radboud University Medical CenterRotterdam Eye HospitalTerminated
-
Jonsson Comprehensive Cancer CenterKite, A Gilead CompanyCompletedClear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
National Center for Research Resources (NCRR)Duke UniversityUnknown